{"id":"W4376613834","doi":"10.1016/j.esmoop.2023.101571","title":"LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche; Eisai; Sanofi; Daiichi-Sankyo; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Internal medicine; Cyclophosphamide; Oncology; Adjuvant; Neoadjuvant therapy; Capecitabine; Placebo; Population; Breast cancer; Gastroenterology; Surgery; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009678893,0.0005311138,0.001703881,0.0001718755,0.0003443942,0.0001346778,0.001199267,0.0001230069,0.0002767514],"category_scores_gemma":[0.0001714457,0.0003338701,0.0003159815,0.001259573,0.0001690604,0.00004729377,0.0008175197,0.0001908816,0.000003934812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002628753,"about_ca_system_score_gemma":0.0006015568,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01828023,"about_ca_topic_score_gemma":0.004822812,"domain_scores_codex":[0.9964333,0.0006036661,0.0009043538,0.0009038872,0.0005681662,0.0005866917],"domain_scores_gemma":[0.9978528,0.0001639079,0.0008748649,0.0007296926,0.0002564432,0.0001223178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9629312,0.00147342,0.01325365,0.00001193579,0.006728318,0.00001122265,0.0008458624,0.001083507,0.001769396,0.000002237428,0.002598594,0.009290655],"study_design_scores_gemma":[0.939201,0.001650147,0.04827001,0.000122483,0.001396441,0.000001245947,0.0002662044,0.003059551,0.005427382,0.000005958643,0.0001570655,0.0004424881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988985,0.0001125191,0.0000351778,0.0005780088,0.0002184156,0.008587884,0.001208023,0.00001625451,0.000258727],"genre_scores_gemma":[0.9929057,0.0001414424,0.0001157712,0.0001612265,0.00005716,0.003543806,0.0005601101,0.00006283412,0.002451942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03501636,"threshold_uncertainty_score":0.9999113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03329605026677972,"score_gpt":0.359875093027282,"score_spread":0.3265790427605023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}